

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

The Journal of Prevention of Alzheimer's Disease

journal homepage: www.elsevier.com/locate/tjpad

Letter to the Editor

Health-economic challenges for new Alzheimer's disease treatments



ARTICLE INFO

Keywords:

Health economics
Alzheimer's disease
Cost-effectiveness modeling
Real-World Evidence

1. Introduction

After decades of drug development setbacks, the Alzheimer's disease (AD) research field is now experiencing major innovation across diagnostics and therapies. The first amyloid-targeting drugs for early-stage AD are available on the market in multiple countries. Yet these scientific breakthroughs have not translated into positive reimbursement decisions, as appraisal processes to date, including those in major health systems such as the United Kingdom (UK), France and Australia, have resulted in negative decisions. It is possible that these drugs will not become widely available in Europe. Many concerns hinder reimbursement, including the drug costs outweighing the benefits, uncertainty regarding both meaningfulness and long-term efficacy beyond trial follow-up periods, and safety considerations related to serious side effects. The 9th International Pharmaco-Economic Collaboration on Alzheimer's Disease (IPECAD) meeting in Glasgow, Scotland in November 2025 brought together leading experts from academia, industry, regulatory bodies, and patient organizations to reflect on these challenges and chart future directions. We summarize the proceedings under three main topics. For details we refer to abstract and presentation slides on the IPECAD website www.ipecad.org.

2. Advances in cost-effectiveness modeling

Health-economic modeling approaches have evolved alongside ongoing debates about the value and affordability of new AD interventions. At this conference, multiple innovations were presented, including the development of new microsimulation model designs, various options for incorporating treatment effects, exploratory work in deep learning models, and the use of advanced statistical models on disease progression data from trials or observational studies. New theoretical models were introduced to more rigorously quantify health-related quality of life of informal caregivers. Improved estimates of utility and caregiving time were drawn from diverse data sources to cover the wider AD severity spectrum. Transparency, open-sourcing, and cross-country validation were emphasized as critical steps to increase the validity and generalizability of AD health-economic models. A systematic review of evidence on biomarker diagnostics underscored

how diagnostic value depends on downstream intervention strategies, but separating the value of diagnostics from amyloid-targeting therapies in economic evaluation remains a topic for discussion. Discussions on the impact of diagnostic strategies to efficiently identify the target population eligible for treatment and their associated budget impact are needed when introducing amyloid-targeting therapies.

3. The role of registries and real-world evidence

Despite progress in health-economic modeling, substantial decision uncertainty persists, particularly on the translation of relatively small effects on clinical outcomes from 18-month trial results to lifetime, patient relevant changes in disease progression and independent functioning. Other uncertainties relate to how patients and clinicians will behave in seeking a diagnosis and therapy once new therapies become available and how long patients will receive therapy. The potential of real-world data to reduce these uncertainties was discussed. In the United States, regulators have already implemented Coverage with Evidence Development (CED). As different countries may introduce new therapies at different times, phased implementation may create a natural experiment to learn from early adopters, informing treatment patterns, safety monitoring, and real-world effectiveness evidence. However, concerns were raised about whether registries can produce meaningful, unbiased, and high-quality evidence given their non-randomized designs, as well as about their added costs and operational complexities for reimbursement decisions. The International Registry for Alzheimer's Disease and Other Dementias (InRAD) Foundation outlined its efforts to offer an efficient and scalable infrastructure to accelerate international collaboration on standardized evidence collection. The field now has the opportunity to harmonize real-world evidence collection that can shape not only current but also future generations of AD therapies.

4. Are health systems ready?

Changes in AD management raise concerns about the required infrastructure for biomarker testing and the administration of amyloid-targeting therapies. Representatives from patient groups and clinical

<https://doi.org/10.1016/j.tjpad.2026.100575>

Received 19 February 2026; Received in revised form 9 April 2026; Accepted 13 April 2026

Available online 24 April 2026

2274-5807/© 2026 Published by Elsevier Masson SAS on behalf of SERDI Publisher. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

initiatives highlighted system-level challenges, including diagnostic and treatment capacity, safety monitoring, workforce limitations, geographic variability, registry data-collection capabilities, and the need for cultural change within healthcare providers. New delivery pathways and service models have been designed for the broader domain of brain health in terms of risk factor management for primary prevention, early detection and drug treatment. In low- and middle-income countries, the limited availability of health-economic evidence constrains value assessments of whether current prices are justified.

5. Looking forward

The AD health-economics field has benefited from improving data and methods over time. However, there remain opportunities for innovation in the design and evaluation of new interventions. There is a need for international alignment on collecting real-world evidence and sharing health-economic models. Future modeling efforts may incorporate pre-symptomatic stages, reflecting both therapeutic and 'brain health' perspectives for the prevention of dementia. Care pathways should integrate risk identification, early diagnosis and treatment, comprehensive care needs, and caregiver support across the disease spectrum. Generating robust evidence that links biomarker endpoints to long-term outcomes will facilitate more efficient clinical trials and faster access to innovative treatments. With these continued advancements, the future of AD health-economics holds exciting opportunities to refine the evaluation of innovative interventions, paving the way for more accessible care.

AI statement

During the preparation of this work the authors used Microsoft Teams in order to transcribe the conference presentations and ChatGPT to support in summarizing the contents and grammatical correction. After using these tools/services, the authors reviewed and edited the content as needed and take full responsibility for the content of this published work.

CRediT authorship contribution statement

Jinjing Fu: Writing – review & editing, Writing – original draft. **Anders Sköldunger:** Writing – review & editing, Writing – original draft. **Angela Bradshaw:** Conceptualization. **Hana Marie Broulíková:** Conceptualization. **Chiara C Brück:** Conceptualization. **Jack M. Chapel:** Conceptualization. **Sabine Grimm:** Conceptualization. **Anna Hansson:** Conceptualization. **William L. Herring:** Writing – review & editing, Supervision, Conceptualization. **Jakub Hlávka:** Conceptualization. **Men Thi Hoang:** Conceptualization. **Linus Jönsson:** Writing – review & editing, Supervision, Conceptualization. **Filipa Landeiro:** Conceptualization. **Javier Mar:** Conceptualization. **Alison McKean:** Conceptualization. **Matej Misik:** Conceptualization. **Peter Neumann:** Conceptualization. **Thomas Rapp:** Conceptualization. **Craig Ritchie:** Conceptualization. **Anja Schiel:** Conceptualization. **Yi Sun:** Conceptualization. **Dominic Trépel:** Conceptualization. **David Trueman:** Conceptualization. **P.J. van der Veere:** Conceptualization. **Lynn van Rosmalen:** Conceptualization. **Jean L Vonsy:** Conceptualization. **Lizzie Walker:** Conceptualization. **Anders Wimo:** Writing – review & editing, Supervision, Conceptualization. **Bengt Winblad:** Writing – review & editing, Supervision, Conceptualization. **Xin Xia:** Conceptualization. **Ron Handels:** Writing – review & editing, Supervision, Project administration, Conceptualization.

Declaration of competing interest

Angela Bradshaw is employee of Alzheimer Europe which receives grants and support for its activities from the European Union's Citizens, Equality, Rights and Values (CERV) and Horizon Europe programmes,

from the Luxembourg National Research Fund (FNR), as well as from private and public organisations and companies, including AbbVie, Alector, Alzheon, BioArctic, Biogen, Bristol Myers Squibb, C2N Diagnostics, Eisai, Essity, GE Healthcare, J&J Healthcare, Lilly, Merck Sharp & Dohme, Nutricia, Prothena, and Roche. All funding is paid to his institution.

Hana Marie Broulíková reports no conflict of interest related to this work. Her work was supported by the Ministry of Health of the Czech Republic, grant no. NW24J-07-00064.

Chiara C Brück reports no conflict of interest related to this work.

Jack Chapel reports in the past 3 years received funding from the National Institutes of Health, the National Bureau of Economic Research, and Genentech. He is also supported by the USC Schaeffer Center for Health Policy and Economics, which receives funding from various agencies, organizations, and corporations, including Lilly.

Jinjing Fu reports no conflict of interest related to this work.

Sabine Grimm reports no conflict of interest related to this work.

Anna Hansson: reports no conflict of interest related to this work.

William L. Herring is a full-time employee of RTI Health Solutions, an independent nonprofit research organization. His compensation is unconnected to the studies on which he works. RTI Health Solutions did not receive funding for the current study. Outside of this study, RTI Health Solutions receives funding pursuant to research contracts with pharmaceutical and biotechnology companies. William L. Herring is affiliated to research at the Karolinska Institutet and receives no compensation as part of this affiliation.

Ron Handels received outside this study consulting fees in the past 36 months from Lilly Nederland and from the Institute for Medical Technology Assessment (paid to institution).

Jakub Hlávka reports no conflict of interest related to this work. His work was supported from ERDF/ESF project Ageing of the population and related challenges for health and social systems (AGEING-CZ) (No. CZ.02.01.01/00/23_025/0008743).

Men Thi Hoang reports no conflict of interest related to this work.

Filipa Landeiro reports no conflict of interest related to this work.

Linus Jönsson reports the following outside this work: research funding and consultancy fees from the following pharmaceutical companies: Novo Nordisk, Eli Lilly, Eisai and Lundbeck.

Javier Mar reports no conflict of interest related to this work.

Alison McKean reports no conflict of interest related to this work.

Matej Misik reports no conflict of interest related to this work.

Peter Neumann reports grants or contracts from National Pharmaceutical Council (NPC), Arnold Ventures, AstraZeneca, Argenx; Moore Foundation; consulting fees from Sarepta, Patient Square Capital, Analysis Group, Avalere, Johnson and Johnson; Participation on a Data Safety Monitoring Board or Advisory Board from Advisory boards on health economic issues for Merck, Argenx, Pfizer.

Thomas Rapp reports no conflict of interest related to this work.

Craig Ritchie reports CEO, Founder and Majority Shareholder in Scottish Brain Sciences that has or has had commercial contracts with the following companies: Lilly, Roche, Roche Diagnostics, Therini, MSD, Merck, Actinogen, Eisai, Novartis, Janssen Cilag and Linus Health.

Anja Schiel: reports no conflict of interest related to this work.

Anders Sköldunger reports no conflict of interest related to this work.

Yi Sun reports no conflict of interest related to this work.

Dominic Trépel reports no conflict of interest related to this work.

David Trueman reports shareholder, Director, and employee of a company which receives consulting fees from Eisai (related to this work) and Biogen (unrelated to this work).

Pieter van der Veere reports no conflict of interest related to this work.

Lynn van Rosmalen reports no conflict of interest related to this work.

Jean L Vonsy is a consultant for InRAD.

Lizzie Walker reports no conflict of interest related to this work.

Anders Wimo reports the following outside this work: PREDEM

(Vinnova), Addition (JPND), EURO-FINGER (JPND), PROMINENT (IHI), PRODEMOS (H2020). All payment to my department. Royalties: License holder of RUD-instrument (part). Member of ADÍ MSAP (unpaid).

Bengt Winblad: reports no conflict of interest related to this work.

Xin Xia reports no conflict of interest related to this work.

The sponsors of this IPECAD conference were: Eisai, BioArctic, Lilly, and Roche. David Trueman provided a sponsor-invited talk.

Acknowledgement

We thank the conference speakers for their contributions to the discussions that informed this conference proceedings letter. In alphabetical order, we acknowledge Angela Bradshaw (Alzheimer Europe, Luxembourg), Chiara Brück (Erasmus MC Rotterdam, Netherlands), Hana Marie Broulikova (VU Amsterdam, Netherlands), Jack Chapel (University of Southern California (USC), United States), Sabine Grimm (Maastricht UMC+, Netherlands), Jakub Hlávka (Masaryk University, Czech Republic), Men Hoang (Trinity College Dublin, Ireland), Filipa Landeiro (University of Oxford, United Kingdom), Alison McKean (Alzheimer Scotland, United Kingdom), Matej Mišík (Masaryk University, Czech Republic), Javier Mar (Biogipuzkoa Research Institute, Spain), Peter Neumann (CEVR, Tufts Medical Center, United States), Becky Pennington (University of Sheffield, United Kingdom), Thomas Rapp (Université Paris Cité, France), Craig Ritchie (Scottish Brain Sciences & University of St Andrews, United Kingdom), Anja Schiel (Norwegian Medical Products Agency, Norway), Yi Sun (University of Reading, United Kingdom), Dominic Trépel (Trinity College Dublin / Global Brain Health Institute, Ireland), David Trueman (Source Health Economics, United Kingdom), Pieter van der Veere (Amsterdam UMC, Netherlands), Lynn van Rosmalen (Erasmus MC, Netherlands), Jean L. Vonsy (InRAD foundation, The Netherlands), Lizzie Walker (NICE, United Kingdom), and Xin Xia (Karolinska Institutet, Sweden) for their presentations and insights during the meeting. IPECAD conference steering group: Jinjing Fu, Ron Handels, Anna Hansson, Will Herring, Linus Jonsson, Anders Skoldunger, Anders Wimo, Bengt Winblad. We thank Anna Hansson for her support in the organization of the conference. We thank Jinjing Fu and Anders Skoldunger for their role in drafting the conference proceedings. We thank Inge de Kok (Erasmus MC, Netherlands) for her contribution in preparing the presentation for the IPECAD workshop. We would like to acknowledge the sponsors of this IPECAD conference: Eisai, BioArctic, Lilly, and Roche. David Trueman provided a sponsor-invited talk.

Jinjing Fu^a , Anders Sköldunger^b , Angela Bradshaw^c, Hana Marie Broulíková^{d,e} , Chiara C Brück^f , Jack M. Chapel^g , Sabine Grimm^h , Anna Hansson^b, William L. Herring^{b,i} , Jakub Hlávka^j, Men Thi Hoang^{k,l} , Linus Jönsson^b , Filipa Landeiro^m, Javier Marⁿ, Alison McKean^o, Matej Misik^j , Peter Neumann^p , Thomas Rapp^q, Craig Ritchie^{r,s}, Anja Schiel^t , Yi Sun^u, Dominic Trépel^{k,v}, David Trueman^w, P.J. van der Veere^{x,y} , Lynn van Rosmalen^f , Jean L. Vonsy^z , Lizzie Walker^{aa}, Anders Wimo^b, Bengt Winblad^b , Xin Xia^b, Ron Handels^{b,ab,*} 

^a University Medical Center Groningen, Groningen, The Netherlands

^b Karolinska Institutet, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Solna, Sweden
^c Alzheimer Europe, Senningerberg, Luxembourg
^d National Institute of Mental Health, Klecany, Czechia
^e Faculty of Science, Vrije Universiteit Amsterdam, The Netherlands
^f Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands
^g University of Southern California, Los Angeles, United States
^h Maastricht University Medical Centre+, Maastricht, Netherlands
ⁱ Health Economics, RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC 27709, USA
^j Health Economics, Policy and Innovation Institute, Masaryk University, Brno, Czech Republic
^k Trinity College Dublin, School of Medicine, Dublin, Ireland
^l Manchester Centre for Health Economics, The University of Manchester, Greater Manchester, United Kingdom
^m Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
ⁿ Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain
^o Alzheimer Scotland, Edinburgh, Scotland
^p Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, United States
^q LIRAES and Chaire AgingUP!, Université Paris Cité, Paris, France
^r Scottish Brain Sciences, Edinburgh, United Kingdom
^s University of St Andrews, St Andrews, Scotland, United Kingdom
^t Norwegian Medical Products Agency, Oslo, Norway
^u Department of Economics, University of Reading, United Kingdom
^v Global Brain Health Institute, Dublin, Ireland
^w Source Health Economics, London, United Kingdom
^x Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands
^y Department of Epidemiology and Data Science, Amsterdam UMC, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
^z InRAD Foundation, Deventer, The Netherlands
^{aa} National Institute for Health and Care Excellence, London, United Kingdom
^{ab} Maastricht University, Alzheimer Centre Limburg, Faculty of Health Medicine and Life Sciences, Mental Health and Neuroscience Research Institute, Department of Psychiatry and Neuropsychology, Maastricht, The Netherlands

* Corresponding author.

E-mail address: ron.handels@maastrichtuniversity.nl (R. Handels).